Takeda gains novel drug discovery tech through Envoy acquisition
This article was originally published in Scrip
Takeda's late 2010 research alliance with Envoy Therapeutics has led to the Japanese firm acquiring 100% of the privately held US CNS drug discovery specialist for up to $140 million in cash, in a deal expected to be finalized within the next few days.
You may also be interested in...
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.